A Study to Evaluate the Safety and Efficacy of RQC for AMD
Public ClinicalTrials.gov record NCT05062486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Study identification
- NCT ID
- NCT05062486
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2021
- Primary completion
- Nov 6, 2024
- Completion
- Nov 6, 2024
- Last update posted
- Jul 29, 2025
2021 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Zaparackas M.D. & Knepper M.D. Ph.D., Ltd | Chicago | Illinois | 60611 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Age-related Macular Degeneration trials
Other public records listing Age-related Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT06662162: Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration Recruiting
- NCT06237127: Effects of Goji vs. Fiber on Macular Degeneration Recruiting
- NCT05300724: An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration Active, not recruiting
- NCT07605468: Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension Not yet recruiting
- NCT07594236: Phase 1 Study of C.001 in Retinal Degeneration Recruiting
- NCT06593405: The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05062486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2025 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05062486 live on ClinicalTrials.gov.